Pfizer has launched a new medication for migraine treatment. The company has introduced Rimegepant ODT in India for adults with a previous insufficient response to triptan, the usual drugs for treating migraine.
The new medication delivers rapid and sustained pain relief lasting up to 48 hours post-treatment, while not associated with the risk of medication overuse headaches. Rimegepant will be available in a 75 mg orally disintegrating tablet (ODT) form, designed for convenient administration without the need for water.
Pfizer is engaged in manufacturing, marketing, trading and export of pharmaceutical products.
